What are the indications, contraindications, and recommended protocol for therapeutic phlebotomy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Therapeutic Phlebotomy: Indications, Contraindications, and Protocol

Therapeutic phlebotomy is the first-line treatment for iron overload disorders, particularly hereditary hemochromatosis and polycythemia vera, with a structured two-phase approach targeting specific ferritin and hematocrit goals.

Primary Indications

The main indications for therapeutic phlebotomy include 1:

  • Hereditary hemochromatosis (HFE-related and other forms)
  • Polycythemia vera
  • Secondary erythrocytosis (COPD, post-renal transplant, congenital cyanotic heart disease)
  • Iron overload from other causes
  • Testosterone replacement therapy-related polycythemia

Contraindications and When to Pause Treatment

Absolute contraindications:

  • Hemoglobin <11 g/dL - phlebotomy must be discontinued 1
  • Severe anemia from other causes
  • Hemodynamic instability or severe cardiac impairment 1

Relative contraindications requiring dose adjustment:

  • Hemoglobin <12 g/dL - reduce frequency or volume 1
  • Advanced liver disease with poor tolerance
  • Pregnancy (though not absolutely contraindicated; can be performed with careful monitoring)

Protocol for Hemochromatosis

Induction Phase 1

Volume and frequency:

  • Remove 400-500 mL weekly or every 2 weeks
  • Continue until target ferritin of 50 μg/L is achieved

Monitoring schedule:

  • Check hemoglobin before each phlebotomy session
  • Measure ferritin every month (or after every 4th phlebotomy)
  • Once ferritin drops below 200 μg/L, check ferritin every 1-2 treatment sessions

Hemoglobin-based adjustments:

  • If Hb <12 g/dL: reduce frequency or volume
  • If Hb <11 g/dL: pause treatment entirely and investigate for other causes of anemia

Maintenance Phase 1

Target and frequency:

  • Target ferritin: 50-100 μg/L
  • Frequency: typically 2-6 phlebotomies per year (highly variable between patients)
  • Average ferritin rises approximately 100 μg/L per year without treatment

Monitoring schedule:

  • Check hemoglobin before each session
  • Monitor ferritin and transferrin saturation every 6 months
  • Life-long follow-up required

Protocol for Polycythemia Vera

Target hematocrit 2, 3:

  • Women: <42%
  • Men: <45%

Procedure:

  • Fixed volume of 350 mL every 3 days until target achieved 2
  • Alternatively, weekly phlebotomies can be performed
  • Continue maintenance phlebotomy to keep hematocrit below target

Alternative Treatment Options

Erythrocytapheresis 1

When to consider:

  • Patients who cannot tolerate standard phlebotomy hemodynamically
  • When faster iron depletion is desired
  • Availability and local expertise permit

Advantages:

  • Fewer hemodynamic changes
  • Fewer procedures needed in induction phase
  • Returns valuable blood components

Disadvantages:

  • Mild citrate reactions are common
  • More expensive than standard phlebotomy
  • Same target ferritin goals (Induction: 50 μg/L, Maintenance: 50-100 μg/L)

Iron Chelation Therapy 1

Only use as second-line treatment when phlebotomy is not feasible after careful risk-benefit assessment by a specialist.

Options:

  • Deferasirox (DFX): 10-15 mg/kg oral, most studied but off-label
  • Deferoxamine (DFO): subcutaneous infusion, can combine with mini-phlebotomies
  • Deferiprone (DFP): oral, very limited experience, risk of agranulocytosis

Contraindications for all chelators:

  • Pregnancy
  • Advanced liver disease (especially for DFX)
  • Renal failure (requires dose adjustment)

Monitoring for DFX:

  • Monthly liver and renal function
  • Audiological and ophthalmological review before starting and annually

Critical Patient Counseling 1

Dietary modifications (do NOT substitute for phlebotomy):

  • Avoid iron supplements and iron-fortified foods
  • Avoid supplemental vitamin C (enhances iron absorption)
  • Limit red meat consumption
  • Restrict alcohol intake; complete abstinence if advanced liver disease

Safety considerations:

  • Avoid raw/undercooked seafood
  • Avoid contact of wounds with seawater (Vibrio vulnificus risk)

Adjunctive therapy:

  • Proton pump inhibitors (if prescribed for other indications) can reduce phlebotomy frequency by decreasing iron absorption 1

Common Pitfalls to Avoid

  1. Over-treatment: Ferritin <20 μg/L significantly increases dietary iron absorption and can cause symptomatic iron deficiency 1. Stop before reaching iron deficiency.

  2. Inadequate monitoring: Unexpected changes in ferritin or transferrin saturation warrant investigation for alternative causes (bleeding, malignancy, inflammation) 1.

  3. Sending patients to "just donate blood": This is inappropriate. Therapeutic phlebotomy requires a prescribed course with specific targets and monitoring 4.

  4. Ignoring hemoglobin: Always check hemoglobin before each procedure to prevent anemia 1.

  5. Relaxing targets too much in elderly: While some experts suggest more relaxed maintenance targets (ferritin <200 μg/L for women, <300 μg/L for men), these are based on expert opinion and may compromise outcomes 1.

Special Populations

Juvenile hemochromatosis 1:

  • Phlebotomy is first-line when possible
  • Severe cardiac iron overload may require combination chelation therapy (DFP + DFO)
  • More aggressive approach needed in induction phase

Pregnancy 3:

  • Phlebotomy can be performed if needed
  • If high-risk and requiring cytoreduction, use interferon-alpha (not chelators)

Advanced disease with poor tolerance 1:

  • Consider mini-phlebotomies plus subcutaneous deferoxamine
  • Refer to specialized centers

Blood Donation Eligibility

Patients with uncomplicated hemochromatosis without significant organ damage can serve as regular blood donors during the maintenance phase, making their blood available for transfusion 1. This provides both therapeutic benefit and community value.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.